Bodenhoff Mads sold $811K of ASND

Ascendis Pharma A/S (ASND) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Third Quarter 2026 Financial Results – Q3 2026 product revenue of € 366 million (+89% Y/Y), comprising € 291 million for YORVIPATH ® , € 59 million for SKYTROFA ® , and € 16 million for YUVIWEL ® – Received positive CHMP and COMP

Ascendis Pharma (ASND) reported Q3 2026 revenue of €370M, up 73% YoY, driven by YORVIPATH sales. Operating profit rose to €125M from €11M, and net profit reached €74M, reversing a prior-year loss. The company expects EU marketing authorization for TransCon CNP in Q4 2026 and plans its first EU launch in Germany in Q1 2027. Positive clinical data for TransCon CNP was also presented.

Ascendis Pharma (ASND) announced a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products for its TransCon CNP therapy, supporting potential market exclusivity. The company has a $273.00 price target and a Buy rating from analysts, while TipRanks' AI Analyst rates it as Neutral due to mixed financial and technical factors.

Ascendis Pharma (ASND) announced the European Medicines Agency's Committee for Orphan Medicinal Products recommended maintaining orphan drug designation for TransCon CNP (navepegritide) to treat achondroplasia. This could grant 10 years of market exclusivity upon European Commission approval, expected in Q4 2026. The company aims to launch the drug, branded as YUVIWEL, in Germany in Q1 2027.

Ascendis Pharma (ASND) announced that the EMA's Committee for Orphan Medicinal Products recommended maintaining orphan drug status for TransCon CNP in the EU. This designation, if approved by the European Commission, would grant 10 years of market exclusivity. The company expects a final decision in Q4 2026 and a potential EU launch in Q1 2027. TransCon CNP was approved in the U.S. in February 2026 for treating achondroplasia in children.

The EMA's COMP recommended maintaining orphan designation for Ascendis Pharma's TransCon CNP for achondroplasia in children. If approved by the European Commission, it would grant 10 years of market exclusivity. A final decision is expected in Q4 2026, following U.S. approval in February 2026.